TAM
AZN icon

Trillium Asset Management’s AstraZeneca AZN Stock Holding History

Trillium Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.6M Sell
208,971
-54,536
-21% -$10.3M 1.22% 18
2026
Q1 		$44.4M Buy
263,507
+22,517
+9% +$4.34M 1.47% 12
2025
Q4 		$44.8M Sell
240,990
-46,969
-16% -$8.24M 1.37% 13
2025
Q3 		$44.2M Sell
287,959
-4,990
-2% -$755K 1.17% 20
2025
Q2 		$40.9M Sell
292,949
-31,771
-10% -$4.45M 1.1% 23
2025
Q1 		$47.7M Sell
324,720
-9,626
-3% -$1.39M 1.37% 12
2024
Q4 		$43.8M Sell
334,346
-16,616
-5% -$2.33M 1.14% 17
2024
Q3 		$54.7M Sell
350,962
-5,660
-2% -$914K 1.34% 12
2024
Q2 		$55.6M Sell
356,622
-13,476
-4% -$2.03M 1.4% 13
2024
Q1 		$50.1M Buy
370,098
+3,493
+1% +$463K 1.28% 16
2023
Q4 		$49.4M Sell
366,605
-9,447
-3% -$1.23M 1.35% 14
2023
Q3 		$50.9M Sell
376,052
-1,825
-0.5% -$249K 1.53% 10
2023
Q2 		$54.1M Sell
377,877
-61,591
-14% -$9.06M 1.52% 9
2023
Q1 		$64.2M Buy
439,468
+20,058
+5% +$2.7M 1.88% 5
2022
Q4 		$56.9M Buy
419,410
+9,772
+2% +$1.23M 1.75% 7
2022
Q3 		$44.9M Buy
409,638
+19,645
+5% +$2.49M 1.47% 9
2022
Q2 		$51.5M Buy
389,993
+37,708
+11% +$4.95M 1.58% 7
2022
Q1 		$46.7M Buy
352,285
+21,925
+7% +$2.63M 1.24% 17
2021
Q4 		$38.5M Buy
330,360
+12,831
+4% +$1.51M 0.9% 35
2021
Q3 		$38.1M Buy
317,529
+7,235
+2% +$842K 1.01% 29
2021
Q2 		$37.1M Buy
310,294
+28,247
+10% +$3.1M 1.03% 26
2021
Q1 		$28M Buy
282,047
+28,928
+11% +$2.91M 0.89% 40
2020
Q4 		$25.3M Buy
253,119
+21,556
+9% +$2.28M 0.91% 36
2020
Q3 		$25.4M Sell
231,563
-13,240
-5% -$1.47M 1.07% 29
2020
Q2 		$25.9M Buy
244,803
+26,928
+12% +$2.78M 1.11% 25
2020
Q1 		$19.5M Buy
217,875
+132,186
+154% +$12.4M 1.02% 27
2019
Q4 		$8.54M Buy
85,689
+5,109
+6% +$481K 0.38% 94
2019
Q3 		$7.18M Buy
+80,580
New +$6.99M 0.34% 99

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Trillium Asset Management's AZN Position: Q2 2026 in Review

Trillium Asset Management reduced its AstraZeneca (AZN) stake by 21% in Q2 2026, selling an estimated $10.3M and leaving 208,971 shares worth $39.6M. The position accounts for 1.22% of the portfolio, ranked #18.

Trillium Asset Management first reported a position in AZN in Q3 2019 and has held it in 28 quarters since. The position peaked at $64.2M in Q1 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Trillium Asset Management held 208,971 shares of AstraZeneca worth $39.6M as of Q2 2026.
  • Trillium Asset Management sold 54,536 AstraZeneca shares in Q2 2026, an estimated $10.3M.
  • AstraZeneca made up 1.22% of Trillium Asset Management's portfolio in Q2 2026, its #18 holding.
  • Trillium Asset Management first reported a position in AstraZeneca in Q3 2019 and has held it in 28 quarters since.
  • Trillium Asset Management's AstraZeneca position peaked at $64.2M in Q1 2023.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Trillium Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.